NRG1 and diabetic cardiomyopathy: NRG1 treatment improves volume overload (Wang et al., 2012), adriamycin-induced LV dysfunction (Bian et al., 2009), as well as ischemia (Cohen et al., 2014) and diabetic cardiomyopathy (Li et al., 2011).